April 3, 2020 -- Modalis Therapeutics has licensed intellectual property (IP) from CRISPR-related gene-editing company Editas Medicine.
Through the agreement, Modalis will use CRISPR-Guide Nucleotide Directed Modulation (CRISPR-GNDM) technology to create gene therapies for patients with genetic disorders. Financial terms of the agreement were not disclosed.
Already have an account? Sign in Here
To access all ScienceBoard content create a free account now: